ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress.
Publication
, Conference
Wainberg, Z; Wang, L; Yue, H; Motwani, M; Kasichayanula, S; Blaney, M; Naumovski, L; Strickler, J
Published in: Ann Oncol
June 2018
Duke Scholars
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
June 2018
Volume
29 Suppl 5
Start / End Page
v83 / v84
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Wainberg, Z., Wang, L., Yue, H., Motwani, M., Kasichayanula, S., Blaney, M., … Strickler, J. (2018). ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress. In Ann Oncol (Vol. 29 Suppl 5, pp. v83–v84). England. https://doi.org/10.1093/annonc/mdy151.295
Wainberg, Z., L. Wang, H. Yue, M. Motwani, S. Kasichayanula, M. Blaney, L. Naumovski, and J. Strickler. “ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress.” In Ann Oncol, 29 Suppl 5:v83–84, 2018. https://doi.org/10.1093/annonc/mdy151.295.
Wainberg Z, Wang L, Yue H, Motwani M, Kasichayanula S, Blaney M, et al. ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress. In: Ann Oncol. 2018. p. v83–4.
Wainberg, Z., et al. “ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress.” Ann Oncol, vol. 29 Suppl 5, 2018, pp. v83–84. Pubmed, doi:10.1093/annonc/mdy151.295.
Wainberg Z, Wang L, Yue H, Motwani M, Kasichayanula S, Blaney M, Naumovski L, Strickler J. ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress. Ann Oncol. 2018. p. v83–v84.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
June 2018
Volume
29 Suppl 5
Start / End Page
v83 / v84
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis